Differential inhibition of the prejunctional actions of angiotensin II in rat atria by valsartan, irbesartan, eprosartan, and losartan

Citation
Ss. Shetty et D. Delgrande, Differential inhibition of the prejunctional actions of angiotensin II in rat atria by valsartan, irbesartan, eprosartan, and losartan, J PHARM EXP, 294(1), 2000, pp. 179-186
Citations number
40
Categorie Soggetti
Pharmacology & Toxicology
Journal title
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
ISSN journal
00223565 → ACNP
Volume
294
Issue
1
Year of publication
2000
Pages
179 - 186
Database
ISI
SICI code
0022-3565(200007)294:1<179:DIOTPA>2.0.ZU;2-5
Abstract
The effects of valsartan and other nonpeptide angiotensin II type 1 (AT(1)) receptor blockers on the prejunctional actions of angiotensin II were inve stigated in the isolated left atria of rat. Norepinephrine stores in rat at ria were loaded with [H-3] norepinephrine, and neuronal norepinephrine rele ase was deduced from the radioactivity efflux. Angiotensin II (10(-9) to 10 (-6) M) produced concentration-dependent enhancement of the electrical stim ulation-induced efflux of [H-3] norepinephrine from the preparation. Pretre atment of tissues with valsartan, irbesartan, eprosartan, or losartan (10(- 8) to 10(-6) M) produced concentration- dependent inhibitions of the stimul ation-induced efflux of radioactivity observed in the presence of angiotens in II (10(-7) M). The AT(1) receptor blockers did not decrease the "basal" stimulation-induced overflow of radioactivity but rather selectively inhibi ted the angiotensin II-mediated augmentation of the response. Regression an alyses of the inhibition of the angiotensin II-mediated response by valsart an, irbesartan, eprosartan, and losartan revealed corresponding log IC50 va lues (log M, with 95% confidence intervals) of -7.78 (-8.19, -7.51), -7.65 (-8.02, -7.40), -7.12 (-7.37, -6.86), and -6.75 (-7.00, -6.40), indicating that the IC50 values for valsartan and irbesartan are significantly lower t han those for eprosartan and losartan. Thus, valsartan is a potent inhibito r of the prejunctional facilitatory effect of angiotensin II on the release of norepinephrine from peripheral sympathetic nerves. This implies that th e therapeutic domain of valsartan may be extended to include pathophysiolog ical conditions such as congestive heart failure wherein prejunctional angi otensin II receptors apparently play a significant role. Whether the high p otency of valsartan translates into a significant clinical advantage relati ve to the other agents tested remains to be ascertained.